Brief: Nanoformed Drug Candidate Receives FDA Orphan Drug Designation

Nanoform Finland Oyj

19/10/2023 12:05

Oct 19 (Reuters) - Nanoform Finland Oyj  NANOFH.HE :
    * NANOFORMED TARGTEX ONCOLOGY DRUG CANDIDATE TTX101 RECEIVES
FDA
ORPHAN DRUG DESIGNATION

Source text for Eikon:  ID:nWkr5Q5BMv 
Further company coverage:  NANOFH.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))